🧪
hypothesis

Microbial Metabolite-Mediated α-Synuclein Disaggregation

Hypothesis

Microbial Metabolite-Mediated α-Synuclein Disaggregation

Specific gut bacterial strains produce short-chain fatty acids (SCFAs) that cross the blood-brain barrier and directly modulate α-synuclein aggregation through epigenetic modifications of chaperone proteins.
🧬 SNCA, HSPA1A, DNMT1🩺 neurodegeneration🎯 Composite 51%💱 $0.52▼22.0%proposed
🟡 ALS / Motor Neuron Disease🔴 Alzheimer's Disease🔮 Lysosomal / Autophagy🔥 Neuroinflammation
EvidencePending (0%)📖 22 cit🗣 1 debates 5 support 2 oppose
✓ All Quality Gates Passed
Mechanistic 0.30 (15%) Evidence 0.40 (15%) Novelty 0.80 (12%) Feasibility 0.50 (12%) Impact 0.60 (12%) Druggability 0.40 (10%) Safety 0.70 (8%) Competition 0.60 (6%) Data Avail. 0.40 (5%) Reproducible 0.30 (5%) KG Connect 0.32 (8%) 0.511 composite
🏆 ChallengeBreaking the GBA—α-Synuclein Bidirectional Feedback Loop in Parkinson's Disease$3.0M →
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite51%

🧪 Overview

Specific gut bacterial strains produce short-chain fatty acids (SCFAs) that cross the blood-brain barrier and directly modulate α-synuclein aggregation through epigenetic modifications of chaperone proteins. Therapeutic supplementation with SCFA-producing bacteria could prevent or reverse pathological protein aggregation in PD.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

graph TD
    A["Gut Microbiome<br/>B. longum, F. prausnitzii<br/>A. muciniphila"] --> B["SCFA Production<br/>Butyrate, Propionate<br/>Acetate"]
    B --> C["Blood-Brain Barrier<br/>Crossing via MCT1/MCT2<br/>Transporters"]
    C --> D["HDAC Inhibition<br/>HDAC1, HDAC3, HDAC6<br/>Suppression"]
    D --> E["Histone Hyperacetylation<br/>H3/H4 Acetylation<br/>Chromatin Remodeling"]
    E --> F["HSF1/NF-Y Transcription<br/>Factor Activation"]
    F --> G["HSPA1A Upregulation<br/>Heat Shock Protein 70<br/>Expression"]
    C --> H["DNMT1 Inhibition<br/>DNA Methylation<br/>Reduction"]
    H --> I["Neuroprotective Gene<br/>Demethylation"]
    G --> J["Enhanced Protein<br/>Chaperone Activity"]
    I --> J
    J --> K["alpha-Synuclein<br/>Disaggregation"]
    L["alpha-Synuclein<br/>Pathological Aggregates"] --> K
    K --> M["Reduced Neuronal<br/>Toxicity"]
    M --> N["Neuroprotection<br/>Disease Modification"]
    O["Therapeutic Intervention<br/>SCFA Supplementation<br/>Probiotic Administration"] --> B

⚖️ Evidence

⚖️ Evidence Matrix5 supports2 contradicts
Supports
Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease.
Acta Pharm Sin B2021PMID:34729301medium
Supports
Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.
Autophagy2022PMID:35287553medium
Supports
A ROS-Responsive nanoparticle for nuclear gene delivery and autophagy restoration in Parkinson's disease therapy.
Biomaterials2025PMID:40245457medium
Supports
Preclinical Alzheimer's disease shows alterations in circulating neuronal-derived extracellular vesicle microRNAs in a multiethnic cohort.
Alzheimers Dement2025PMID:40042514medium
Supports
The Crosstalk Between Sepsis-Associated Encephalopathy and Alzheimer's Disease: Identifying Potential Biomarkers and Therapeutic Targets for Cognition.
Mol Neurobiol2025PMID:40634788medium
Contradicts
Short-chain fatty acids produced by gut microbiota promoted microglial activation and motor deficits in an alpha-synuclein Parkinson model, contradicting a uniformly protective SCFA/disaggregation model.
Cell2016PMID:27912057medium
Contradicts
Reviews of SCFAs, alpha-synuclein, neuroinflammation, and redox stress describe bidirectional and context-dependent effects rather than direct disaggregation evidence.
Redox Biol2024PMID:38377788medium
📖 Linked Papers (16)Export BibTeX ↗
Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease.
Autophagy (2020) · PubMed:30966861 ↗
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
Movement disorders : official journal of the Movement Disorder Society (2017) · PubMed:29124790 ↗
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
Utility of Drosophila for studying hypoxia-inducible factor (HIF) in neurodegenerative diseases: Advantages versus limitations.
Brain research (2025) · PubMed:40976499 ↗
No figures
Revisiting Parkinson's disease definition and classification: insights from two emerging biological frameworks.
Journal of neural transmission (Vienna, Austria : 1996) (2025) · PubMed:40906256 ↗
No figures
Uncovering injury-specific proteomic signatures and neurodegenerative risks in single and repetitive traumatic brain injury.
Signal transduction and targeted therapy (2025) · PubMed:40545497 ↗
No figures
Nucleolin inhibits α-synuclein to attenuate aconitine's neurotoxicity.
Phytomedicine : international journal of phytotherapy and phytopharmacology (2025) · PubMed:40482618 ↗
No figures
MEK1/2 inhibitors suppress pathological α-synuclein and neurotoxicity in cell models and a humanized mouse model of Parkinson's disease.
Science translational medicine (2025) · PubMed:40367191 ↗
No figures
Advancing Parkinson's diagnosis: seed amplification assay for α-synuclein detection in minimally invasive samples.
Molecular and cellular biochemistry (2025) · PubMed:39760833 ↗
No figures
High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease.
Acta neuropathologica communications (2021) · PubMed:34742348 ↗
No figures
The role of neuroimaging in Parkinson's disease.
J Neurochem (2021) · PubMed:34532856 ↗
No figures
Mitochondrial Dysfunction and Mitophagy in Parkinson's Disease: From Mechanism to Therapy.
Trends in biochemical sciences (2021) · PubMed:33323315 ↗
No figures
Mitochondria and Parkinson's Disease: Clinical, Molecular, and Translational Aspects.
Journal of Parkinson's disease (2021) · PubMed:33074190 ↗
No figures
📙 Related Wiki Pages (15)
NES ProteinproteinPBKR03entityHSPA1A ProteinproteinSNCA — Alpha-SynucleingeneDNMT1 GenegeneHSPA1A GenegeneSNCA — Alpha-Synuclein Gene Entity PagegeneNatriuretic Peptide Receptor Modulators therapeuticacetylcholine-signaling-neurodegeneratiomechanismMicroglial Priming and Innate Immune ToltherapeuticNT-3 Signaling Pathway in NeurodegeneratmechanismGSK3 Beta in NeurodegenerationmechanismBrain Pericytes in NeurodegenerationcellProtein Aggregation Comparison in NeurodmechanismEpigenetic Dysregulation in Neurodegenermechanism

🏥 Translation

🧬 3D Protein Structure — SNCA

🧬 PDB 1XQ8 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for SNCA, HSPA1A, DNMT1 from GTEx v10.

Cerebellar Hemisphere61.9 Frontal Cortex BA959.1 Anterior cingulate cortex BA2447.5 Cerebellum44.6 Cortex36.0 Spinal cord cervical c-125.7 Amygdala24.9 Nucleus accumbens basal ganglia21.6 Substantia nigra20.8 Hippocampus19.0 Hypothalamus18.5 Caudate basal ganglia13.5 Putamen basal ganglia12.4median TPM (GTEx v10)

💉 Clinical Trials (5)Relevance: 44%

0
Active
0
Completed
282
Total Enrolled
PHASE1
Highest Phase
RAPA-501 Therapy for ALSPHASE2
RECRUITING·NCT04220190 · Rapa Therapeutics LLC
41 enrolled · 2025-01-02 · → 2026-07-01
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Amyotrophic Lateral Sclerosis
RAPA-501 Autologous T stem cells
MAD Phase I Study to Investigate Contraloid AcetatePHASE1
COMPLETED·NCT03955380 · Prof. Dr. Dieter Willbold
24 enrolled · 2018-12-12 · → 2019-04-03
This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a
Alzheimer Dementia Alzheimer Disease
Contraloid
Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain InjuryN/A
UNKNOWN·NCT04820881 · Washington D.C. Veterans Affairs Medical Center
60 enrolled · 2021-10-01 · → 2024-09
This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu
Neurodegenerative Diseases
Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's DiseasePHASE1
NOT_YET_RECRUITING·NCT07212088 · iCamuno Biotherapeutics Ltd.
12 enrolled · 2026-02-28 · → 2027-12-15
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p
Parkinson Disease
ALC01 therapy
MRI Biomarkers in ALSN/A
COMPLETED·NCT02405182 · University of Alberta
145 enrolled · 2014-09 · → 2019-03
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f
Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases
Magnetic Resonance Imaging

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for SNCA, HSPA1A, DNMT1 →

No DepMap CRISPR Chronos data found for SNCA, HSPA1A, DNMT1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development
Cost
$0
Timeline
2.2 years

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▼ 1.5%
Volatility
High
0.0559
Events (7d)
5
Price History
▼22.0%

💾 Resource Usage

LLM Tokens
34,972
$0.2158
Total Cost
$0.2158

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
If hypothesis is true, intervention incorporate engineered bacterial strains with enhanced SCFA production capacity and targeted delivery mechanisms, including synthetic biology approaches to optimizeincorporate engineered bacterial strains with enhanced SCFA production capacity and targeted delivery mechanisms, including synthetic biology approaches to opti— no observation —pending0.40
If hypothesis is true, intervention integrate pharmacogenomic profiling, microbiome analysis, and metabolomic signatures to optimize strain selection and dosing for individual patientsintegrate pharmacogenomic profiling, microbiome analysis, and metabolomic signatures to optimize strain selection and dosing for individual patients— no observation —pending0.40
🔮 Falsifiable Predictions (2)
pendingconf 40%
If hypothesis is true, intervention incorporate engineered bacterial strains with enhanced SCFA production capacity and targeted delivery mechanisms, including synthetic biology approaches to optimize butyrate biosynthetic pathways
Predicted outcome: incorporate engineered bacterial strains with enhanced SCFA production capacity and targeted delivery mechanisms, including synthetic biology approach
Falsification: Intervention fails to incorporate engineered bacterial strains with enhanced SCFA production capacity and targeted delivery mechanisms, including synthetic biology approaches to optimize butyrate bios
pendingconf 40%
If hypothesis is true, intervention integrate pharmacogenomic profiling, microbiome analysis, and metabolomic signatures to optimize strain selection and dosing for individual patients
Predicted outcome: integrate pharmacogenomic profiling, microbiome analysis, and metabolomic signatures to optimize strain selection and dosing for individual patients
Falsification: Intervention fails to integrate pharmacogenomic profiling, microbiome analysis, and metabolomic signatures to optimize strain selection and dosing for individual patients
View on SciDEX ↗